Biotech company ExpreS2ion Biotechnologies develops protein-based vaccines using its platform technology ExpreS2. Today, the pipeline consists of projects in four indications: covid-19, breast cancer, influenza and malaria. The company is currently carrying out a rights issue of 73 million SEK to finance the completion of preclinical studies within the breast cancer project ES2B-C001, as well as to further develop the pipeline and strengthen its platform technology. CEO Bent U. Frandsen tells us more about ExpreS2ion’s vision in today’s BioStock Investor Pitch at 10:00.
See ExpreS2ion Biotechnologies CEO Bent U. Frandsen presents the company, in English, below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.